Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology

BACKGROUND: There are currently no disease-modifying therapeutics for Parkinson’s disease (PD). Although extensive efforts were undertaken to develop therapeutic approaches to delay the symptoms of PD, untreated α-synuclein (α-syn) aggregates cause cellular toxicity and stimulate further disease pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jihoon, Sung, Ki Woon, Bae, Eun-Jin, Yoon, Dabin, Kim, Dasarang, Lee, Jin Saem, Park, Da-ha, Park, Daniel Youngjae, Mun, Su Ran, Kwon, Soon Chul, Kim, Hye Yeon, Min, Joo-Ok, Lee, Seung-Jae, Suh, Young Ho, Kwon, Yong Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290391/
https://www.ncbi.nlm.nih.gov/pubmed/37355598
http://dx.doi.org/10.1186/s13024-023-00630-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290391/
https://www.ncbi.nlm.nih.gov/pubmed/37355598
http://dx.doi.org/10.1186/s13024-023-00630-7

Ejemplares similares